OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture (OsseoFix)
Primary Purpose
Vertebral Compression Fractures
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
OsseoFix Spinal Fracture Reduction System
Sponsored by
About this trial
This is an interventional treatment trial for Vertebral Compression Fractures focused on measuring VCF
Eligibility Criteria
Inclusion Criteria:
- 5o years of age.
- Legal US citizen with ability to read and write.
- Acute painful fracture (≤2 months) between T6 to L5 as evidenced by plain radiography, CT / Bone scan, and/or magnetic resonance imaging.
Subject is...
Non-Standard Treatment:
- Inability to tolerate prolonged conservative care due to intractable pain (VAS 70/100) with maximum tolerated medication for at least 2 weeks, but less than 6 weeks; OR
- Inability to tolerate prolonged immobilization due to other comorbid conditions aggravated by immobility for at least 2 weeks, but less than 6 weeks; OR
- Intolerance of or adverse reaction to available pain medications for at least 2 weeks, but less than 6 weeks; OR
- Hospitalization secondary to pain for at least 2 weeks, but less than 6 weeks.
Standard Treatment:
- Has undergone at least 6 weeks of conservative care.
- Have a self assessment VAS score ≥ 50 mm at the Baseline visit.
- Have 30% or greater disability score on ODI at the Baseline visit.
- Anterior wedge deformity with no less than 5% and no more than 75% loss of anterior cortical height as compared to the posterior cortical height of the same vertebral body.
- Bone mineral density (BMD) T-score of -1.5 or less, as determined by a DEXA scan.
- Intact posterior cortical vertebral body wall.
- Type A compression fractures according to AO classification of spinal vertebral fractures.
- If a transpedicular approach is utilized the pedicle diameter must be equal to or greater than 6.5 mm; however, if an extrapedicular approach is utilized there is not a minimum pedicle width requirement.
- Subject is willing and able to provide informed consent and agrees to release medical information for purposes of this study (HIPAA authorization) and to return for scheduled follow-up evaluations.
Exclusion Criteria:
- Significant vertebral collapse defined as more than 75% of original vertebral height or less than 5% or a burst or pedicle fracture with posterior cortical wall disruption.
- Presence of healed fracture at the intended treatment level(s) based on a CT / bone scan or MRI.
- Compression fractures requiring treatment at 3 or more levels.
- Spinal/Foraminal canal compromised.
Significant deformity/instability indicated by:
- Segmental kyphosis > 30 degrees, or
- translation > 4 mm.
- VAS back pain score of < 50 mm.
- ODI score of < 30%.
- Have a documented active systemic or local infection, such as AIDS, hepatitis, with a WBC greater than 11.5 and a temperature greater than 101.5°F.
- Spinal surgery in the thoracic and/or lumbar region within the past year
- Previous kyphoplasty or vertebroplasty at involved level or level above or below treated level.
- Spinal arthrodesis within 2 adjacent levels of fracture.
- Non-ambulatory prior to fracture.
- Greater than Grade 1 spondylolisthesis at level of fracture.
- Scoliosis > 10 degrees.
- BMI > 40.
- Severe cardiopulmonary deficiencies.
- Pregnant.
- Type I or II diabetes without controlled A1C level.
- Achondrogenesis disorders.
- Active malignancy, hemangiomas at the operative level(s), or multiple myeloma.
- No generally accepted medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy with a threshold for INR at 1.5 or less, and platelet count 100,000.
- A life expectancy less than the study duration or undergoing palliative care.
- Trauma injuries aside from vertebral compression fracture(s).
- Injuries that violate the posterior vertebral cortex and/or posterior column.
- Active litigation.
- Currently on workman's compensation.
- Autoimmune disorders.
- Non-spine pain that requires daily Opioids.
- Systemic long-term steroid use - greater than 6 months.
- Active multiple sclerosis or neurologic deficit caudal to fracture.
- Currently an alcohol, solvent, or drug abuser.
- Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements.
- History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or Zirconium Oxide (ZrO2)
- Incarcerated.
- Are currently participating in another investigational study.
- Having had another device implanted in the thoracic and/or lumbar area that would interfere with the surgical approach, study device, or follow-up evaluations.
Sites / Locations
- Scripps
- Boulder Neurosurgery Associates
- South Denver Neurosurgery
- Lyerly Neurosurgery
- Southwestern Orthopedic Center
- SIU Phyysicians and Surgeons Division of Orthopaedics and Rehabilitation
- Jewish Hospital for Advanced Medicine
- Clinical Radiology of Oklahoma
- NeuroSpine Institute, LLC
- Orthopaedic Associates of the Greater Lehigh Valley Easton Hospital
- Neurospine Solutions, PC
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
OsseoFix
Arm Description
Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
Outcomes
Primary Outcome Measures
Percentage of Participants With Back Pain Improvement at 12 Months
Back pain improvement is defined as a reduction in VAS score of ≥ 20mm at 12 months from baseline
Percentage of Participants With Functional Disability Improvement at 12 Months
Functional disability improvement is defined as a reduction in ODI score by ≥ 15 points at 12 months from baseline.
Absence of Device Related Subsequent Interventions or Re-treatment at the Study Treated Levels
Secondary Outcome Measures
Change in Pain at 12 Months as Presented by VAS, When Compared to Baseline
Pain measurements determined by Visual Analog Scale (VAS) on a 100mm scale with, 0=no pain at all, to 100=worse possible pain.
Functional Disability Change at 12months From Baseline as Determined by ODI
Improvement in functional disability as determined by ODI on a scale of 0-50, with 0=no disability at all to 50=complete disability
Any Cement Extravasation Before Discharge
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00961714
Brief Title
OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture
Acronym
OsseoFix
Official Title
Evaluation of Safety and Effectiveness of the OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Terminated
Why Stopped
Withdrew study
Study Start Date
August 2009 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alphatec Spine, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The OsseoFix Spinal Fracture Reduction System facilitates the treatment of spinal fractures by providing internal fixation and stabilization using a titanium implant in conjunction with OsseoFix+™ polymethylmethacrylate (PMMA) bone cement.
The purpose of the study is to provide reasonable assurance on safety and effectiveness of the OsseoFix Spinal Fracture Reduction System for market release approval in the US.
This investigational device is intended to restore biomechanical integrity to a vertebral body that has suffered a painful compression fracture in the thoracic or lumbar spine between levels T6 and L5.
Detailed Description
This is a prospective, multi-center clinical study designed to evaluate safety and effectiveness of the OsseoFix Spinal Fracture Reduction System used with PMMA bone cement relative to the clinical expectations for treatment of vertebral compression fractures (VCFs). The study will be conducted at up to 15 investigational centers in the United States in 115 (up to 125) subjects with one or two vertebral compression fractures between levels T6 and L5 implanted with the investigational device(s).
Baseline screening will be completed to determine eligible subjects. VCFs will be confirmed by magnetic resonance imaging (MRI), or by a CT / bone scan. These diagnostic tests will be utilized to confirm that there are no retropulsed bone fragments. Subjects who meet all inclusion criteria and do not have any exclusion criteria will be scheduled to receive the OsseoFix Spinal Fracture Reduction System.
Subjects that are enrolled will be implanted with the OsseoFix Spinal Fracture Reduction System through a postero-lateral approach to the anterior vertebral body using instruments specifically designed for this procedure.
Radiographs will be taken at each follow-up visit, including baseline and post-operatively. Subject's perception of pain will be assessed using the Visual Analogue Scale (VAS). Functional outcomes will be measured using the Oswestry Disability Index (ODI) and Short Form- 36 (SF-36) questionnaires as well as their neurologic status. The VAS, ODI, SF-36 and neurologic status will be measured at baseline, 4-week, 3-month, 6-month and 12-month follow-up visits. Overall patient-satisfaction will be evaluated at all post-implant scheduled follow-up visits. Adverse event will be the recorded in all scheduled and non-scheduled visits.
The endpoint analysis will be performed and submitted when all implanted subjects have completed their 12-months follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vertebral Compression Fractures
Keywords
VCF
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
OsseoFix
Arm Type
Experimental
Arm Description
Osseofix is an titanium expandable device similar to a vascular stent that is placed in the fractured vertebral body to provide a structure in which bone cement (polymethylmethacrylate) is inserted. It is intended to be used in the thoracolumbar spine between levels T6 through L5.
Intervention Type
Device
Intervention Name(s)
OsseoFix Spinal Fracture Reduction System
Intervention Description
All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
Primary Outcome Measure Information:
Title
Percentage of Participants With Back Pain Improvement at 12 Months
Description
Back pain improvement is defined as a reduction in VAS score of ≥ 20mm at 12 months from baseline
Time Frame
12 months
Title
Percentage of Participants With Functional Disability Improvement at 12 Months
Description
Functional disability improvement is defined as a reduction in ODI score by ≥ 15 points at 12 months from baseline.
Time Frame
12 months
Title
Absence of Device Related Subsequent Interventions or Re-treatment at the Study Treated Levels
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in Pain at 12 Months as Presented by VAS, When Compared to Baseline
Description
Pain measurements determined by Visual Analog Scale (VAS) on a 100mm scale with, 0=no pain at all, to 100=worse possible pain.
Time Frame
12 months
Title
Functional Disability Change at 12months From Baseline as Determined by ODI
Description
Improvement in functional disability as determined by ODI on a scale of 0-50, with 0=no disability at all to 50=complete disability
Time Frame
12 months
Title
Any Cement Extravasation Before Discharge
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
5o years of age.
Legal US citizen with ability to read and write.
Acute painful fracture (≤2 months) between T6 to L5 as evidenced by plain radiography, CT / Bone scan, and/or magnetic resonance imaging.
Subject is...
Non-Standard Treatment:
Inability to tolerate prolonged conservative care due to intractable pain (VAS 70/100) with maximum tolerated medication for at least 2 weeks, but less than 6 weeks; OR
Inability to tolerate prolonged immobilization due to other comorbid conditions aggravated by immobility for at least 2 weeks, but less than 6 weeks; OR
Intolerance of or adverse reaction to available pain medications for at least 2 weeks, but less than 6 weeks; OR
Hospitalization secondary to pain for at least 2 weeks, but less than 6 weeks.
Standard Treatment:
Has undergone at least 6 weeks of conservative care.
Have a self assessment VAS score ≥ 50 mm at the Baseline visit.
Have 30% or greater disability score on ODI at the Baseline visit.
Anterior wedge deformity with no less than 5% and no more than 75% loss of anterior cortical height as compared to the posterior cortical height of the same vertebral body.
Bone mineral density (BMD) T-score of -1.5 or less, as determined by a DEXA scan.
Intact posterior cortical vertebral body wall.
Type A compression fractures according to AO classification of spinal vertebral fractures.
If a transpedicular approach is utilized the pedicle diameter must be equal to or greater than 6.5 mm; however, if an extrapedicular approach is utilized there is not a minimum pedicle width requirement.
Subject is willing and able to provide informed consent and agrees to release medical information for purposes of this study (HIPAA authorization) and to return for scheduled follow-up evaluations.
Exclusion Criteria:
Significant vertebral collapse defined as more than 75% of original vertebral height or less than 5% or a burst or pedicle fracture with posterior cortical wall disruption.
Presence of healed fracture at the intended treatment level(s) based on a CT / bone scan or MRI.
Compression fractures requiring treatment at 3 or more levels.
Spinal/Foraminal canal compromised.
Significant deformity/instability indicated by:
Segmental kyphosis > 30 degrees, or
translation > 4 mm.
VAS back pain score of < 50 mm.
ODI score of < 30%.
Have a documented active systemic or local infection, such as AIDS, hepatitis, with a WBC greater than 11.5 and a temperature greater than 101.5°F.
Spinal surgery in the thoracic and/or lumbar region within the past year
Previous kyphoplasty or vertebroplasty at involved level or level above or below treated level.
Spinal arthrodesis within 2 adjacent levels of fracture.
Non-ambulatory prior to fracture.
Greater than Grade 1 spondylolisthesis at level of fracture.
Scoliosis > 10 degrees.
BMI > 40.
Severe cardiopulmonary deficiencies.
Pregnant.
Type I or II diabetes without controlled A1C level.
Achondrogenesis disorders.
Active malignancy, hemangiomas at the operative level(s), or multiple myeloma.
No generally accepted medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy with a threshold for INR at 1.5 or less, and platelet count 100,000.
A life expectancy less than the study duration or undergoing palliative care.
Trauma injuries aside from vertebral compression fracture(s).
Injuries that violate the posterior vertebral cortex and/or posterior column.
Active litigation.
Currently on workman's compensation.
Autoimmune disorders.
Non-spine pain that requires daily Opioids.
Systemic long-term steroid use - greater than 6 months.
Active multiple sclerosis or neurologic deficit caudal to fracture.
Currently an alcohol, solvent, or drug abuser.
Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements.
History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or Zirconium Oxide (ZrO2)
Incarcerated.
Are currently participating in another investigational study.
Having had another device implanted in the thoracic and/or lumbar area that would interfere with the surgical approach, study device, or follow-up evaluations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Yue, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Daniel Bennett, MD
Organizational Affiliation
Integrative Treatment Centers
Official's Role
Principal Investigator
Facility Information:
Facility Name
Scripps
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Boulder Neurosurgery Associates
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80304
Country
United States
Facility Name
South Denver Neurosurgery
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80122
Country
United States
Facility Name
Lyerly Neurosurgery
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
Southwestern Orthopedic Center
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Facility Name
SIU Phyysicians and Surgeons Division of Orthopaedics and Rehabilitation
City
Springfield
State/Province
Illinois
ZIP/Postal Code
62702
Country
United States
Facility Name
Jewish Hospital for Advanced Medicine
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Clinical Radiology of Oklahoma
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73034
Country
United States
Facility Name
NeuroSpine Institute, LLC
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
Orthopaedic Associates of the Greater Lehigh Valley Easton Hospital
City
Easton
State/Province
Pennsylvania
ZIP/Postal Code
18045
Country
United States
Facility Name
Neurospine Solutions, PC
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
12. IPD Sharing Statement
Learn more about this trial
OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture
We'll reach out to this number within 24 hrs